29 related articles for article (PubMed ID: 30304553)
1. GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells.
Dallons M; Alpan E; Schepkens C; Tagliatti V; Colet JM
Cells; 2020 Sep; 9(10):. PubMed ID: 32992522
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib combined with doxorubicin causes dose-dependent cardiotoxicity partially through activating the p38MAPK signaling pathway in zebrafish embryos.
Du K; Liu Y; Zhang L; Peng L; Dong W; Jiang Y; Niu M; Sun Y; Wu C; Niu Y; Ding Y
Biomed Pharmacother; 2024 Jun; 175():116637. PubMed ID: 38653111
[TBL] [Abstract][Full Text] [Related]
3. Novel molecular mechanisms of doxorubicin cardiotoxicity: latest leading-edge advances and clinical implications.
Robert Li Y; Traore K; Zhu H
Mol Cell Biochem; 2024 May; 479(5):1121-1132. PubMed ID: 37310587
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of doxorubicin-dihydroartemisinin prodrug/TEPP-46 nano-liposomes for improving antitumor and decreasing cardiotoxicity in B16-F10 tumor-bearing mice.
Jin Q; Zhou X; Niu X; Ping C; Dong X; Duan D; Wang R; Chen Y; Pan F; Yang F; Yang X; Zhang G; Wang R; Zhang S; Ren G
Colloids Surf B Biointerfaces; 2024 May; 241():113992. PubMed ID: 38833960
[TBL] [Abstract][Full Text] [Related]
5. The ameliorative effect of rosmarinic acid and epigallocatechin gallate against doxorubicin-induced genotoxicity.
Helvacioglu S; Charehsaz M; Bankoglu EE; Stopper H; Aydin A
Drug Chem Toxicol; 2024 Mar; ():1-13. PubMed ID: 38529831
[TBL] [Abstract][Full Text] [Related]
6. Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients.
Ebaid NF; Abdelkawy KS; Shehata MA; Salem HF; Magdy G; Hussein RRS; Elbarbry F
Xenobiotica; 2024 Mar; 54(3):160-170. PubMed ID: 38491961
[TBL] [Abstract][Full Text] [Related]
7. Dual delivery of carbon monoxide and doxorubicin using haemoglobin-albumin cluster: proof of concept for well-tolerated cancer therapy.
Ito C; Taguchi K; Yamada T; Hanaya K; Enoki Y; Sugai T; Komatsu T; Matsumoto K
J Mater Chem B; 2024 Jun; 12(23):5600-5608. PubMed ID: 38738920
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients.
Chang WT; Lin YW; Ho CH; Chen ZC; Liu PY; Shih JY
Arch Toxicol; 2021 Feb; 95(2):659-671. PubMed ID: 33211168
[TBL] [Abstract][Full Text] [Related]
9. EPAC1 inhibition protects the heart from doxorubicin-induced toxicity.
Mazevet M; Belhadef A; Ribeiro M; Dayde D; Llach A; Laudette M; Belleville T; Mateo P; Gressette M; Lefebvre F; Chen J; Bachelot-Loza C; Rucker-Martin C; Lezoualch F; Crozatier B; Benitah JP; Vozenin MC; Fischmeister R; Gomez AM; Lemaire C; Morel E
Elife; 2023 Aug; 12():. PubMed ID: 37551870
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis and Anti-Platelet Aggregation Activity Study of Ginkgolide-1,2,3-triazole Derivatives.
Cui J; Hu L; Shi W; Cui G; Zhang X; Zhang QW
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181694
[TBL] [Abstract][Full Text] [Related]
11. A Novel Danshensu Derivative Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer Cells.
Wang L; Zhang X; Chan JY; Shan L; Cui G; Cui Q; Wang Y; Li J; Chen H; Zhang Q; Yu P; Han Y; Wang Y; Lee SM
J Cell Biochem; 2016 Jan; 117(1):94-105. PubMed ID: 26058377
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CACNA1H attenuates doxorubicin-induced acute cardiotoxicity by affecting endoplasmic reticulum stress.
Hu J; Wu Q; Wang Z; Hong J; Chen R; Li B; Hu Z; Hu X; Zhang M
Biomed Pharmacother; 2019 Dec; 120():109475. PubMed ID: 31580970
[TBL] [Abstract][Full Text] [Related]
13. Endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity may be therapeutically targeted by natural and chemical compounds: A review.
Yarmohammadi F; Rezaee R; Haye AW; Karimi G
Pharmacol Res; 2021 Feb; 164():105383. PubMed ID: 33348022
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.
Nicoletto RE; Ofner CM
Cancer Chemother Pharmacol; 2022 Mar; 89(3):285-311. PubMed ID: 35150291
[TBL] [Abstract][Full Text] [Related]
15. A novel agent attenuates cardiotoxicity and improves antitumor activity of doxorubicin in breast cancer cells.
Zhang Y; Deng H; Zhou H; Lu Y; Shan L; Lee SM; Cui G
J Cell Biochem; 2019 Apr; 120(4):5913-5922. PubMed ID: 30304553
[TBL] [Abstract][Full Text] [Related]
16. A novel compound DT-010 protects against doxorubicin-induced cardiotoxicity in zebrafish and H9c2 cells by inhibiting reactive oxygen species-mediated apoptotic and autophagic pathways.
Tang F; Zhou X; Wang L; Shan L; Li C; Zhou H; Lee SM; Hoi MP
Eur J Pharmacol; 2018 Feb; 820():86-96. PubMed ID: 29229534
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
